As for MET amplifications, they are typically present in 2 to 5% of newly diagnosed adenocarcinomas, presenting higher incidence in NSCLC patients following erlotinib/gefitinib treatment (5 to 22%) and are also common in NSCLC brain metastasis. This evidence concerns the gene MET and non-small cell lung carcinoma.